Benorylate (Salipran) is the esterification product of paracetamol and acetylsalicylic acid. Benorylate has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit prostaglandin (PG) synthesis.

Product information

CAS Number: 5003-48-5

Molecular Weight: 313.30

Formula: C17H15NO5

Chemical Name: 4-acetamidophenyl 2-(acetyloxy)benzoate

Smiles: CC(=O)NC1C=CC(=CC=1)OC(=O)C1=CC=CC=C1OC(C)=O

InChiKey: FEJKLNWAOXSSNR-UHFFFAOYSA-N

InChi: InChI=1S/C17H15NO5/c1-11(19)18-13-7-9-14(10-8-13)23-17(21)15-5-3-4-6-16(15)22-12(2)20/h3-10H,1-2H3,(H,18,19)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 125 mg/mL (398.98 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Benorylate (Salipran) is an esterified aspirin preparation whose antirheumatic properties are reported to be as good as those of aspirin. Benorylate (Salipran) causes a large decrease in the liver’s conversion rate of lactate into glucose, an important component of glucose homeostasis. Benorylate (Salipran) also impairs the urea synthesis rate from ammonia, another important function of the liver.

In Vivo:

Benorylate (Salipran) is probably absorbed as the intact molecule which accounts for its good gastric tolerance. Benorylate (Salipran) could inhibit PG synthesis in laboratory animals and in human tissue.

Products are for research use only. Not for human use.